Danatlas Pharmaceuticals announced that the Investigational New Drug (IND) application for DAT‑6618, an independently developed PPARγ inhibitor, has been approved by China’s National Medical Products Administration (NMPA). DAT‑6618 is the first PPARγ inhibitor in China to enter clinical research, marking a new breakthrough in the company’s precision targeting of transcription factors in oncology.
Contents
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | IND clearance for clinical trials |
| Product | DAT‑6618 (novel oral small molecule) |
| Modality | Highly selective PPARγ inverse agonist |
| First‑in‑Country Status | First PPARγ inhibitor to enter clinical research in China |
| Approval Date | 18 September 2026 |
| Next Steps | Clinical trial initiation; dosing and schedule details not yet disclosed |
Drug Profile & Mechanism of Action
- Molecule: A novel, oral, highly selective PPARγ inverse agonist, independently developed by Danatlas.
- Target Engagement: Upon binding the PPARγ/RXRα heterodimer, DAT‑6618 promotes corepressor binding while blocking coactivator binding, thereby suppressing PPARγ‑driven downstream gene expression.
- Disease Biology: PPARγ, a transcription factor and nuclear receptor, can activate tumour cell growth and promote immune escape, rendering tumour cells insensitive to immune checkpoint inhibitors (ICI).
- Target Population: Tumours with PPARγ overexpression or RXRα gain‑of‑function mutations, including bladder cancer, gastrointestinal tumours and endometrial cancer.
- Therapeutic Concept: By inverting PPARγ signalling, DAT‑6618 offers a precision‑oncology approach with potential to resensitise ICI‑refractory tumours – detailed clinical hypotheses to be tested in upcoming trials.
Pipeline Snapshot
| Asset | Target / Modality | Status |
|---|---|---|
| DAT‑6618 | PPARγ inverse agonist | IND approved by NMPA (Sep 2026) – first PPARγ inhibitor in clinical research in China |
| DAT‑2645 | PARG inhibitor | Phase II clinical study – first PARG inhibitor in clinical research in China |
| Multiple innovative products | Various | Advanced to clinical stage |
Market Impact & Outlook
- Transcription Factor Frontier: DAT‑6618’s IND clearance extends Danatlas’s strategy beyond its synthetic lethality core strength into targeting transcription factors that play key roles in tumorigenesis – historically considered “undruggable” targets.
- Leadership Vision: Chairman and CEO Dr. Zhou Wenlai stated that the company is consolidating its advantages in the synthetic lethality field while continuously deploying against transcription factor targets, aiming to open a new treatment landscape for solid tumour patients.
- Precision Oncology Positioning: A biomarker‑defined population (PPARγ‑high / RXRα‑mutant tumours) aligns with the trend toward genetically stratified cancer therapy, potentially enabling differentiated trial designs and accelerated development paths.
- Pipeline Momentum: With DAT‑2645 already in Phase II and multiple assets in the clinic, Danatlas is demonstrating sustained execution across its transcription‑factor and DNA‑damage‑response portfolio.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding DAT‑6618’s clinical development, regulatory timelines and therapeutic potential. Actual results may differ due to risks including trial outcomes, safety findings, regulatory requirements and competitive dynamics in the oncology market.-Fineline Info & Tech
